Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.

Trial Details

NCT ID
NCT07089199
Phase
PHASE2
Sponsor
Qilu Hospital of Shandong University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • neoadjuvant therapy
  • Surgery
  • Adjuvant therapy
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Age 18-75 years old, gender is not limited;
  • Histologically confirmed Stage III non-small cell lung cancer (AJCC Stage 8th edition)
  • The tumor is resectable after assessment by the attending surgeon
  • EGFR/ALK mutation negative or unknown (unknown only for squamous non-small cell lung cancer)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →